<?xml version='1.0' encoding='utf-8'?>
<document id="28286567"><sentence text="Grazoprevir/elbasvir combination therapy for HCV infection."><entity charOffset="0-11" id="DDI-PubMed.28286567.s1.e0" text="Grazoprevir" /></sentence><sentence text="Interferon-free regimens combine different second-wave direct-acting antiviral agents (DAAs), which target the main viral proteins involved in the replication cycle of hepatitis C virus (HCV): NS3/4A protease inhibitors (simeprevir or paritaprevir boosted by ritonavir), NS5B nucleos(t)idic (sofosbuvir) and nonnucleos(t)idic (dasabuvir) polymerase inhibitors, NS5A replication complex inhibitors (daclatasvir, ledipasvir, elbasvir, velpatasvir)"><entity charOffset="235-247" id="DDI-PubMed.28286567.s2.e0" text="paritaprevir" /><entity charOffset="259-268" id="DDI-PubMed.28286567.s2.e1" text="ritonavir" /><entity charOffset="292-302" id="DDI-PubMed.28286567.s2.e2" text="sofosbuvir" /><entity charOffset="398-409" id="DDI-PubMed.28286567.s2.e3" text="daclatasvir" /><entity charOffset="411-421" id="DDI-PubMed.28286567.s2.e4" text="ledipasvir" /><entity charOffset="423-431" id="DDI-PubMed.28286567.s2.e5" text="elbasvir" /><entity charOffset="433-444" id="DDI-PubMed.28286567.s2.e6" text="velpatasvir" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e0" e2="DDI-PubMed.28286567.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e0" e2="DDI-PubMed.28286567.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e0" e2="DDI-PubMed.28286567.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e0" e2="DDI-PubMed.28286567.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e0" e2="DDI-PubMed.28286567.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e0" e2="DDI-PubMed.28286567.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e0" e2="DDI-PubMed.28286567.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e1" e2="DDI-PubMed.28286567.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e1" e2="DDI-PubMed.28286567.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e1" e2="DDI-PubMed.28286567.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e1" e2="DDI-PubMed.28286567.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e1" e2="DDI-PubMed.28286567.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e1" e2="DDI-PubMed.28286567.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e2" e2="DDI-PubMed.28286567.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e2" e2="DDI-PubMed.28286567.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e2" e2="DDI-PubMed.28286567.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e2" e2="DDI-PubMed.28286567.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e2" e2="DDI-PubMed.28286567.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e3" e2="DDI-PubMed.28286567.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e3" e2="DDI-PubMed.28286567.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e3" e2="DDI-PubMed.28286567.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e3" e2="DDI-PubMed.28286567.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e4" e2="DDI-PubMed.28286567.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e4" e2="DDI-PubMed.28286567.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e4" e2="DDI-PubMed.28286567.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e5" e2="DDI-PubMed.28286567.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28286567.s2.e5" e2="DDI-PubMed.28286567.s2.e6" /></sentence><sentence text=" Combinations of two or three DAAs, given for 8-24 weeks reach sustained virology response (SVR) rates greater than 90% with good tolerance" /><sentence text=" SVR rates and safety are similar in clinical trials and in real life, usually higher than 95% in the per-protocol analysis" /><sentence text=" Next-generation DAAs are now expected" /><sentence text=" To be competitive, these new combinations need to prove their added value regarding the pill burden, the reduced duration of treatment, the drug-drug interaction profile and safety" /><sentence text=" Zepatier is a fixed-dose combination product coformulating MK-5172 [grazoprevir (GZR), 100 mg QD] and MK-8742 [elbasvir or (EBR) 50 mg QD]: it combines highly potent inhibitors of the HCV NS3/4A protease and NS5A replication complex, respectively"><entity charOffset="103-110" id="DDI-PubMed.28286567.s7.e0" text="MK-8742" /></sentence><sentence text=" This review provides a summary of the main evidence available for the use of GZR/EBR and highlights the strength of this combination" /><sentence text="" /></document>